Member Info for EarlofAim

Can copl survive from here?

where does it says January admin?

Revenue is vanity

profit is sanity

since ipo has MMAG made profit

hence its up for sale

management got fed up with loss making entity

USA alone has 25k kidney transplant per annum

Thermo Fisher has worldwide partnership with VRCI

let's crunch some numbers

25,00 X $2650 per tests is $66M,

now say they do double tests then it's $132M revenue per year on USA alone,

rest of the world not taken into account yet.

Remember VRCI are best in class tests!!!

Today's rns is a fantastic opportunity to buy vrci. and the fact sp not moved gives me to load up at these bargain SP

Thermo Fisher are not stupid..... they have world class researchers at their disposable who decided to partner with VRCI.

market makers are asleep in this

Today's bagger?

let this sink in....

With 63.9 m patients

per tests $2650 that's 169 billion market

Mcap only £19m

Let USA investors wake up to this news

Already Partnership with Thermo Fisher (multi billion dollars company)

bargain SP

Took a while for investors to realise how good the #Crcl prospects was,

glad this done over 400% and continuing.......

GLA

Earl does it again

With 63.9 m patients

per tests $2650 that's 169 billion market

Mcap only £19m💥

#vrci

I feel this will rise when markets wakes up to this news

Fund managers will be buying these at cheap prices

With 63.9 m patients

per tests $2650 that's 169 billion market

Mcap only £19m💥

#vrci

I feel this will rise when markets wakes up to this news

Fund managers will be buying these at cheap prices

Has anyone seen VRCI rns?

$169 billion market with 63.4 m patients

per tests $2650

Mcap only £19m

worth a look

Medicare National Payment Rate for Tutivia? and Clarava? Effective as of January 1, 2024

CMS finalises gapfill median rate at $2,650 per test

Mcap only £19m

cash c£6m

this is the beginning of something special here

Wow!!

$2650 per test and X 63.9m is $169 billion market to be fulfilled by the likes of VRCI

this is huge potential to become mid tier company

Medicare National Payment Rate for Tutivia? and Clarava? Effective as of January 1, 2024

CMS finalises gapfill median rate at $2,650 per test

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule ("CLFS") payment rate of $2,650 established through the "gapfill" process for both Tutivia? (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava? (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.

Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients.

AGL started the Pharma /bio tech bull run

Very early stage, long way to commercialising.

seen with INSP taking ages to get to phase 2, then to next level

it's good news, but nothing finalised yet!!!

Where's my lucky charms today

petroinvestor and Davy50

up 81%

You're welcome Masonmaster

I can only post what's most missed.

Hoping my two Lucky charm turns up here

petroinvestor and Davy50

then Sp will boom more

AGL buy 16p

c4xf 11.8p

trls 4p

yes Earl of AIM is not perfect, but tries

GLA

Nationwide health plan in its final stages in negotiations with USA Large health company

cash is ridiculously high compare to Mcap